A Phase 1b Study of LY2157299 in Combination With Gemcitabine in Patients With Advanced or Metastatic Unresectable Pancreatic Cancer (H9H-JE-JBAO)

Trial Profile

A Phase 1b Study of LY2157299 in Combination With Gemcitabine in Patients With Advanced or Metastatic Unresectable Pancreatic Cancer (H9H-JE-JBAO)

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Jun 2017

At a glance

  • Drugs Galunisertib (Primary) ; Gemcitabine
  • Indications Pancreatic cancer
  • Focus Adverse reactions
  • Sponsors Eli Lilly
  • Most Recent Events

    • 01 Jun 2017 Results assessing the safety, tolerability, efficacy and pharmacokinetics of galunisertib in combination with gemcitabine in patients with metastatic or locally advanced pancreatic cancer, published in the Cancer Chemotherapy and Pharmacology.
    • 09 Feb 2016 Status changed from recruiting to completed as per ClinicalTrials.gov record.
    • 15 Dec 2015 Planned End Date changed from 1 Oct 2016 to 1 Jan 2017 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top